Abstract: The present document relates to pyrazolopyrimidine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the pyrazolopyrimidine compounds, or a tautomeric form and/or salt thereof, are of Formula I: Formula I wherein R1 to R4 are as defined herein.
| # | Name | Date |
|---|---|---|
| 1 | 202447068777-STATEMENT OF UNDERTAKING (FORM 3) [11-09-2024(online)].pdf | 2024-09-11 |
| 2 | 202447068777-PROOF OF RIGHT [11-09-2024(online)].pdf | 2024-09-11 |
| 3 | 202447068777-PRIORITY DOCUMENTS [11-09-2024(online)].pdf | 2024-09-11 |
| 4 | 202447068777-POWER OF AUTHORITY [11-09-2024(online)].pdf | 2024-09-11 |
| 5 | 202447068777-FORM 18 [11-09-2024(online)].pdf | 2024-09-11 |
| 6 | 202447068777-FORM 1 [11-09-2024(online)].pdf | 2024-09-11 |
| 7 | 202447068777-FIGURE OF ABSTRACT [11-09-2024(online)].pdf | 2024-09-11 |
| 8 | 202447068777-DECLARATION OF INVENTORSHIP (FORM 5) [11-09-2024(online)].pdf | 2024-09-11 |
| 9 | 202447068777-COMPLETE SPECIFICATION [11-09-2024(online)].pdf | 2024-09-11 |
| 10 | 202447068777-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [11-09-2024(online)].pdf | 2024-09-11 |
| 11 | 202447068777-FORM 3 [11-03-2025(online)].pdf | 2025-03-11 |
| 12 | 202447068777-RELEVANT DOCUMENTS [13-10-2025(online)].pdf | 2025-10-13 |